Depemokimab review found fewer asthma flare-ups, with mixed results on other outcomes
Trials in severe eosinophilic asthma reported fewer exacerbations and some quality-of-life improvement. Other symptom and lung-function outcomes showed no statistically significant differences, and safety findings varied.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The pooled trials favored depemokimab for asthma flare-ups, including events requiring hospital or emergency care, and for a respiratory quality-of-life score. However, several other measures showed no statistically significant differences. Allergic rhinitis was more frequent with the drug. These findings concern severe eosinophilic asthma and do not establish its longer-term benefit or safety.
The authors identify a small trial base and relatively short follow-up. The abstract does not specify the comparison treatment or follow-up lengths, limiting interpretation of the effect estimates and the longer-term balance of benefits and harms.
Benefits varied by endpoint
A respiratory quality-of-life questionnaire improved, while the asthma control questionnaire, lung function and asthma diary measures showed no statistically significant differences. These outcomes assess different parts of asthma, so an improvement in one does not imply improvement across all measures.
Safety findings need context
Some reported events, including pneumonia and nasopharyngitis, were less frequent, whereas allergic rhinitis was more frequent. Serious adverse events showed no statistically significant difference; that result does not prove equal safety, particularly over longer periods.
The original publication
Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.
Gill BA, Ijaz A, Fatima N et al.
BMC Immunol · 2025
- PubMed ID
- 41331792
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.